Taysha Gene Therapies (TSHA) Interest Expenses (2020 - 2026)

Taysha Gene Therapies has disclosed Interest Expenses across 7 years of filings, most recently posting $9000.0 for Q1 2026.

• Interest Expenses for Q1 2026 came in at $9000.0, down 52.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $53000.0 (down 42.39% YoY), and the FY2025 annual result was $63000.0, down 38.24% from the prior year.
• Interest Expenses came in at $9000.0 for Q1 2026 at Taysha Gene Therapies, down from $12000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $1.5 million in Q3 2023 to a low of $9000.0 in Q1 2026.
• The 5-year median for Interest Expenses is $29000.0 (2024), against an average of $527647.1.
• Across the five-year window, Interest Expenses surged 282.99% in 2022 and slumped 98.37% in 2024, its largest moves.
• Taysha Gene Therapies' Interest Expenses stood at $1.3 million in 2022, then slumped by 45.36% to $713000.0 in 2023, then plunged by 96.91% to $22000.0 in 2024, then sank by 45.45% to $12000.0 in 2025, then declined by 25.0% to $9000.0 in 2026.
• The last three Interest Expenses figures came in at $9000.0 (Q1 2026), $12000.0 (Q4 2025), and $15000.0 (Q3 2025), per Business Quant data.